JP7281450B2 - セレブロリシンの使用 - Google Patents

セレブロリシンの使用 Download PDF

Info

Publication number
JP7281450B2
JP7281450B2 JP2020512835A JP2020512835A JP7281450B2 JP 7281450 B2 JP7281450 B2 JP 7281450B2 JP 2020512835 A JP2020512835 A JP 2020512835A JP 2020512835 A JP2020512835 A JP 2020512835A JP 7281450 B2 JP7281450 B2 JP 7281450B2
Authority
JP
Japan
Prior art keywords
cadasil
cerebrolysin
pharmaceutical composition
patients
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531568A5 (enExample
JP2020531568A (ja
Inventor
シュテファン・ヴィンター
ヘルベルト・メスラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ever Neuro Pharma GmbH
Original Assignee
Ever Neuro Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ever Neuro Pharma GmbH filed Critical Ever Neuro Pharma GmbH
Publication of JP2020531568A publication Critical patent/JP2020531568A/ja
Publication of JP2020531568A5 publication Critical patent/JP2020531568A5/ja
Application granted granted Critical
Publication of JP7281450B2 publication Critical patent/JP7281450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
JP2020512835A 2017-08-28 2018-08-28 セレブロリシンの使用 Active JP7281450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin
EP17188180.8 2017-08-28
PCT/EP2018/073106 WO2019042983A1 (en) 2017-08-28 2018-08-28 USE OF CERBROLYSINE

Publications (3)

Publication Number Publication Date
JP2020531568A JP2020531568A (ja) 2020-11-05
JP2020531568A5 JP2020531568A5 (enExample) 2021-08-12
JP7281450B2 true JP7281450B2 (ja) 2023-05-25

Family

ID=59745228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512835A Active JP7281450B2 (ja) 2017-08-28 2018-08-28 セレブロリシンの使用

Country Status (15)

Country Link
US (1) US12589118B2 (enExample)
EP (2) EP3449931B1 (enExample)
JP (1) JP7281450B2 (enExample)
KR (1) KR102676274B1 (enExample)
CN (1) CN111050780B (enExample)
AU (1) AU2018326339A1 (enExample)
CA (1) CA3073991A1 (enExample)
EA (1) EA202090108A1 (enExample)
ES (2) ES2767070T3 (enExample)
HR (1) HRP20200031T1 (enExample)
MX (1) MX2020002267A (enExample)
PH (1) PH12020500376A1 (enExample)
PL (2) PL3449931T3 (enExample)
UA (1) UA129400C2 (enExample)
WO (1) WO2019042983A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198037A1 (en) * 2019-03-25 2020-10-01 The University Of Vermont Methods to promote cerebral blood flow in the brain
EP4114843B1 (en) 2020-07-13 2023-08-16 EVER Neuro Pharma GmbH Method for producing a mammalian brain protein hydrolysate
KR20240159455A (ko) * 2021-06-02 2024-11-05 리제너론 파마슈티칼스 인코포레이티드 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501967A (ja) 2008-08-20 2012-01-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 調節放出型多粒子のホットメルト押出成形

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE154608T1 (de) 1990-04-12 1997-07-15 Ebewe Arzneimittel Verwendung einer mischung von peptiden and aminosäuren für die prophylaxis oder behandlung von dementia
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501967A (ja) 2008-08-20 2012-01-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 調節放出型多粒子のホットメルト押出成形

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Neurological Sci., 2012, Vol.322, p.2-10
Neurol Sci., 2013, Vol.34, p.553-556

Also Published As

Publication number Publication date
WO2019042983A1 (en) 2019-03-07
JP2020531568A (ja) 2020-11-05
US20200376040A1 (en) 2020-12-03
PH12020500376A1 (en) 2020-12-07
ES2901508T3 (es) 2022-03-22
CA3073991A1 (en) 2019-03-07
AU2018326339A1 (en) 2020-03-05
EP3449931A1 (en) 2019-03-06
EP3675879A1 (en) 2020-07-08
CN111050780A (zh) 2020-04-21
CN111050780B (zh) 2023-11-03
PL3449931T3 (pl) 2020-06-01
UA129400C2 (uk) 2025-04-16
KR102676274B1 (ko) 2024-06-18
MX2020002267A (es) 2020-10-22
EP3675879B1 (en) 2021-09-15
EA202090108A1 (ru) 2020-03-31
ES2767070T3 (es) 2020-06-16
HRP20200031T1 (hr) 2020-03-20
KR20200045503A (ko) 2020-05-04
PL3675879T3 (pl) 2022-02-14
US12589118B2 (en) 2026-03-31
EP3449931B1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
JP7862354B2 (ja) 補体活性のモジュレーター
US9480658B2 (en) Modulation of synaptic maintenance
JP2000507828A (ja) アルツハイマー病の診断および治療法
CN102548571A (zh) 用于预防和治疗脑部疾病和疾病状态的组合物和方法
US12589118B2 (en) Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation
Dhapola et al. Exploring retinal neurodegeneration in Alzheimer’s disease: a molecular and cellular perspective
JP2020518678A (ja) ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用
KR20070103009A (ko) 뇌혈류를 증가시키는 방법
Wang et al. Age-and sex-specific regulation of serine racemase in the retina of an Alzheimer's disease mouse
EP3137099B1 (en) Dnase for use in treating vaso-occlusive crisis
HK40026040B (en) Cerebrolysin for use in the treatment of cadasil
EP4212167A1 (en) Peptide composition for prevention or treatment of alzheimer's disease
EA040978B1 (ru) Применение церебролизина
Cordano et al. Inflammation in the anterior visual pathway in multiple sclerosis: what do the animal models teach us?
Doshmanziari et al. Neuroprotective effects of Human Adipose-Derived Stem Cells in AD rat model focusing on CD11b and Synaptophysin
Jiang The effect of remote ischemic preconditioning on astrocyte phenotypes and responses
Schuler The Role of ASC Specks as Essential Cofactor in Amyloid β-induced Pathophysiology
Tanik The interplay between Lewy body-like alpha-synuclein aggregates and protein degradation pathways in a cell-based model of Parkinson's disease
KR20240111792A (ko) 생물학적 장벽 기능장애를 치료하기 위한 sco-스폰딘-유래 폴리펩타이드
WO2024098034A2 (en) Nanozyme and use for treating neurode generative disease
Hayes Cellular Mechanisms of IGF-1 Neuroprotection After Ischemic Stroke
WO2025049979A1 (en) Hydrophobically interspaced charged peptides for preventing or treating apoe and/or amyloid beta pathologic interaction in alzheimer's disease and related dementias
Banfi et al. A CASE OF CHRONIC IMMUNE SENSORY POLIRADICU-LOPATHY (CISP) RESPONSIVE TO IMMUNE MODULATING TREATMENT
Kane Erica A. Kane 1, 2 Nicholas A. Cruickshanks 2, 3 Lin Zhao Sean 1 P. Cregan 2, 3 Shawn N. Whitehead
Yu Effects of ghrelin on doxorubicin-induced toxicity in skeletal muscle

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230515

R150 Certificate of patent or registration of utility model

Ref document number: 7281450

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250